Sage Therapeutics (NASDAQ:SAGE) PT Lowered to $25.00 at HC Wainwright

Sage Therapeutics (NASDAQ:SAGE) had its price objective cut by HC Wainwright from $28.00 to $25.00 in a research note issued to investors on Friday morning, Benzinga reports. They currently have a neutral rating on the biopharmaceutical company’s stock. HC Wainwright also issued estimates for Sage Therapeutics’ Q1 2025 earnings at ($1.62) EPS, Q2 2025 earnings at ($1.59) EPS, Q3 2025 earnings at ($1.13) EPS and Q4 2025 earnings at ($1.15) EPS.

Other research analysts have also issued reports about the stock. Needham & Company LLC restated a hold rating on shares of Sage Therapeutics in a research report on Thursday. Truist Financial reduced their price target on shares of Sage Therapeutics from $22.00 to $18.00 and set a hold rating for the company in a research report on Friday. JPMorgan Chase & Co. boosted their price target on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an overweight rating in a research report on Tuesday, March 26th. Wedbush restated a neutral rating and set a $24.00 price target on shares of Sage Therapeutics in a research report on Wednesday, April 17th. Finally, The Goldman Sachs Group reduced their price target on shares of Sage Therapeutics from $28.00 to $19.00 and set a neutral rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Sage Therapeutics has an average rating of Hold and a consensus price target of $37.72.

Sage Therapeutics Price Performance

Shares of SAGE stock opened at $13.69 on Friday. The company’s fifty day simple moving average is $18.56 and its two-hundred day simple moving average is $20.64. Sage Therapeutics has a 1 year low of $10.92 and a 1 year high of $59.99.

Sage Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($1.80) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.63) by ($0.17). Sage Therapeutics had a negative net margin of 552.52% and a negative return on equity of 54.17%. The business had revenue of $7.90 million for the quarter, compared to the consensus estimate of $5.26 million. During the same period in the previous year, the firm earned ($2.46) EPS. The company’s revenue was up 139.4% compared to the same quarter last year. Research analysts anticipate that Sage Therapeutics will post -6.3 EPS for the current year.

Institutional Trading of Sage Therapeutics

Several hedge funds have recently added to or reduced their stakes in SAGE. CWM LLC lifted its stake in Sage Therapeutics by 274.2% in the third quarter. CWM LLC now owns 1,205 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 883 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its stake in shares of Sage Therapeutics by 95.5% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,531 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 748 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Sage Therapeutics by 17.4% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,289 shares of the biopharmaceutical company’s stock valued at $191,000 after acquiring an additional 1,375 shares during the last quarter. Values First Advisors Inc. bought a new position in shares of Sage Therapeutics during the third quarter valued at about $219,000. Finally, Quest Partners LLC bought a new position in shares of Sage Therapeutics during the fourth quarter valued at about $261,000. 99.22% of the stock is owned by institutional investors.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.